This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Compugen (CGEN) have performed compared to their sector so far this year.
Is Certara (CERT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Certara, Inc. (CERT) and Compugen (CGEN) have performed compared to their sector so far this year.
Ensign Group (ENSG) Ups Credit Facility to $600M to Fuel Growth
by Zacks Equity Research
Ensign Group (ENSG) expands its credit facility by $250 million to continue with its series of acquisitions, renovation of projects, business requirements et al.
UnitedHealth (UNH) to Spend $5.4B on Home-Health Profile Boost
by Zacks Equity Research
UnitedHealth (UNH) intends to combine its Optum business with LHC Group to expand its reach in the healthcare-at-home market.
UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Refresh Mental Health comes at a time when demand for behavioral health services is on the rise.
Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
Ensign Group (ENSG) expects annual revenues for 2022 in the band of $2.93-$2.98 billion, whose midpoint signals a 12.4% rise from the 2021 reported figure.
Compugen (CGEN) Stock Up on Bristol Myers' $20M Investment
by Zacks Equity Research
Compugen (CGEN) announces an expansion of its collaboration agreement with Bristol Myers Squibb and a $20 million equity investment by the latter.
Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?
by Zacks Equity Research
On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.
Insight Enterprises' (NSIT) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Insight Enterprises' (NSIT) Q3 performance benefits from acquisition of PCM amid sluggish demand from Asia Pacific and EMEA.
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.
What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.
What's in Store for Selecta (SELB) This Earnings Season?
by Zacks Equity Research
In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.
Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.
How Compugen (CGEN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 8th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 8th.
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Compugen (CGEN) a New Strong Buy Stock
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for April 30th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th.
Company News for Mar 10, 2020
by Zacks Equity Research
Companies In The News Are: COCP, CGEN, AAPL, NINE
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compugen (CGEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).